2 models fit SBC Medical Group Holdings Incorporated Common Stock and they disagree: 0 of 2 land within 15% of the average.
Two or more of our models back this value.
Discount(i)Gold82
Valued as a cyclical company: P/E comparison, EV/EBITDA comparison, Discounted cash flow, and Graham number.
ACCE opinionSBC Medical Group Holdings Incorporated Common Stock (SBC)
Fair value (2 models)
$6.43
ACCE price target
$5.72
Rating
Undervalued
Horizon
12 months
Fair value published on 21 Oct 2026, 12:04 CEST; previously $6.13 since 16 Oct 2026, 00:00 CEST.
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Rating published on 21 Oct 2026, 12:04 CEST.
Price used: $5.28 at the close on 23 Oct 2026, 22:00 CEST.
Models: P/E comparison and Graham number.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
17.8% below
+21.7% to fair value
ACCE score
89
out of 100
Analysts
100% buy
3 covering
P/E
11.2x
forward 9.8x
1-year return
+35.0%
Dividend yield
0.00%
SBC Medical Group Holdings Incorporated Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
SBC Medical Group operates aesthetic and cosmetic surgery clinics in Japan, bringing together physicians, medical staff and patient-facing services under one platform, and it reports a business that earns a 71.9% gross margin and a 38.6% operating margin. Those margins are far above what most consulting or services businesses earn, which suggests pricing power and a model that scales well once clinics are established. Revenue is growing 13.4% a year, and at an 11.3 trailing P/E and 9.3 forward P/E the market is pricing the stock as a low-growth business despite that rate of expansion. The company has a 18.9% return on equity and a 545M USD market cap with no index membership, so coverage is thin and the gap between price and fundamentals may persist until it attracts more attention. The score of 88/100 is worth checking against the underlying filings, particularly how much of the margin reflects recurring patient demand versus one-off procedure volume, before deciding whether it merits deeper work.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
high
Insider selling dominates
Insiders hold 81.5% of shares, and the last 10 disclosed transactions show $46.92M in sales against $0.12M in buys. Concentrated insider selling can signal limited confidence and thin free float.
moderate
Flat five-year revenue
Five-year revenue CAGR is -0.1%, even though the latest year shows +13.4%. The recent acceleration has not yet been sustained over a longer period.
moderate
Revenue fell last quarter
Quarter-over-quarter revenue dropped 8.7%, which sits awkwardly beside the strong annual growth figure and is worth checking against the next report.
AI research notes
AI-assisted·How I use AIWritten Oct 24, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Free cash flow of $37M over the last 12 months gives the stock a 6.4% free cash flow yield at the current price.
Revenue grew 13.4% year over year, and the shares trade at a trailing P/E of 11.2x against a 23.3x sector median forward P/E.
Why it could disappoint
Revenue has fallen 0.1% a year on average over five years, so the recent 13.4% jump may not last.
The diluted share count rose 6.7% in the last fiscal year, which dilutes what each share earns.
The latest earnings per share missed expectations by 16.7%, coming in at 0.10 against 0.12 expected.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 13, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where SBC's valuation models land
Price
$5.28
Model fair value
$6.43
Model range
$5.23 to $7.62
Fair value $6.43
Price $5.28
The price sits inside the model range.
Model
Fair value
Upside
Discounted cash flow
EV/EBITDA comparison
Graham number
P/E comparison
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores